Financial Statements

Taysha Gene Therapies, Inc. (TSHA)


-0.00 (-0.29%)
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers are in thousands

Retained Earning Schedule

Year 2022 2021 2020 2019
Retained Earnings (Previous Year) -236-61-1-
Net Income -166-175-60-
Stock Dividends 0---1
Dividend Paid ----
Retained Earnings -401-236-61-1

PPE Schedule

Year 2022 2021 2020 2019
Gross PPE 510--
Annual Depreciation -4669-
Capital Expenditure -21-15-9-
Net PPE 26510-

Intangible and Goodwill Schedule

Year 2022 2021 2020 2019
Intangible and Goodwill (Previous Year) ----
New Purchases ----
Intangible and Goodwill ----

Taysha Gene Therapies, Inc. income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Taysha Gene Therapies, Inc. FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.